|
gptkbp:instanceOf
|
gptkb:drug
HIV drug
|
|
gptkbp:approvedBy
|
gptkb:FDA
2012
|
|
gptkbp:ATCCode
|
J05AG04
|
|
gptkbp:bioavailability
|
high
|
|
gptkbp:CASNumber
|
1004316-88-4
|
|
gptkbp:chemicalFormula
|
C40H53N7O5S2
|
|
gptkbp:combines
|
gptkb:elvitegravir
emtricitabine
tenofovir
|
|
gptkbp:contraindication
|
severe liver impairment
concomitant use with certain drugs metabolized by CYP3A
|
|
gptkbp:developedBy
|
gptkb:Gilead_Sciences
|
|
gptkbp:drugClass
|
cytochrome P450 inhibitor
|
|
gptkbp:eliminationHalfLife
|
3-4 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
cobicistat
|
|
gptkbp:increases_plasma_concentration_of
|
antiretroviral drugs
|
|
gptkbp:indication
|
HIV-1 infection
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
Tybost
|
|
gptkbp:mechanismOfAction
|
CYP3A inhibitor
|
|
gptkbp:molecularWeight
|
776.02 g/mol
|
|
gptkbp:not_active_against
|
gptkb:HIV
|
|
gptkbp:proteinBinding
|
97-98%
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
jaundice
rash
increased serum creatinine
|
|
gptkbp:usedFor
|
pharmacokinetic enhancer
|
|
gptkbp:bfsParent
|
gptkb:CYP3A5
gptkb:tenofovir_disoproxil_fumarate
gptkb:elvitegravir
gptkb:Prezista
|
|
gptkbp:bfsLayer
|
6
|